Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin drug strategy.

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

Eli Lilly & Co.’s stock was on pace for its worst day in about three years Thursday as investors fretted about intensifying competition among obesity-drug developers. Lilly’s stock LLY was ...

While this adds competition to a market currently controlled by Eli Lilly LLY-2.84 % decrease; red down pointing triangle and Novo Nordisk, it also reinforces the dominance of the makers of Wegovy ...

Eli Lilly's anti-obesity drug Zepbound (tirzepatide) receives approval in the US and recommended approval in the EU. The SELECT study data shows that semaglutide 2.4 mg reduces major adverse ...

Eli Lilly & Co.'s stock was on pace for its worst day in about three years Thursday as investors fretted about intensifying competition among obesity-drug developers. Lilly's stock (LLY) was down ...

Amgen (AMGN) and Pfizer (PFE) could soon be snacking on Novo Nordisk (NVO) and Eli Lilly's (LLY) lunch in the anti-obesity market, says Morningstar. Read more here.

For Novo, the Morgan Stanley team expects obesity revenues of $11.7 billion in 2030, while Lilly’s tirzepatide—assuming it clinches an obesity green light—could make around $5.4 billion over ...

Rhythm Pharmaceuticals develops medicines for rare disorders that cause weight gain. The company's only approved product is ...

Eli Lilly’s daily anti-obesity pill orforglipron appears to be as good at spurring weight loss and lowering blood sugar in diabetes patients as popular injectable GLP-1 drugs like Ozempic, ...

Eli Lilly & Co.’s experimental weight-loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug’s blockbuster potential in the company’s ...

Eli Lilly shares fell after the drugmaker warned that sales of its hot diabetes and anti-obesity drugs are growing more slowly than expected. Lilly now expects fourth-quarter sales of $3.5 billion ...